$Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial$

Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial

Bibliographic Details
Main Authors:	DiNardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Bluemmert, I, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S
Format:	Conference item
Language:	English
Published:	American Society of Hematology 2021

Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify Trial

Similar Items